MIM
NVCR icon

MetLife Investment Management’s NovoCure NVCR Stock Holding History

MetLife Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$616K Sell
56,470
-460
-0.8% -$5.75K ﹤0.01% 1653
2025
Q4 		$736K Sell
56,930
-5,787
-9% -$74.3K ﹤0.01% 1592
2025
Q3 		$810K Hold
62,717
– – ﹤0.01% 1578
2025
Q2 		$1.12M Sell
62,717
-1,509
-2% -$26.3K 0.01% 1247
2025
Q1 		$1.14M Sell
64,226
-1,093
-2% -$24.8K 0.01% 1292
2024
Q4 		$1.95M Buy
65,319
+3,716
+6% +$78.6K 0.01% 1059
2024
Q3 		$963K Buy
61,603
+34,711
+129% +$629K 0.01% 1407
2024
Q2 		$461K Buy
26,892
+20,511
+321% +$361K ﹤0.01% 1763
2024
Q1 		$99.7K Buy
6,381
+20
+0.3% +$294 ﹤0.01% 2540
2023
Q4 		$95K Buy
+6,361
New +$85.1K ﹤0.01% 2632
2023
Q3 		– Sell
-6,445
Closed -$267K – 2953
2023
Q2 		$267K Buy
6,445
+185
+3% +$11.5K ﹤0.01% 2089
2023
Q1 		$376K Buy
6,260
+15
+0.2% +$1.2K ﹤0.01% 1820
2022
Q4 		$458K Sell
6,245
-165
-3% -$12.4K ﹤0.01% 1696
2022
Q3 		$487K Buy
6,410
+5
+0.1% +$390 ﹤0.01% 1653
2022
Q2 		$445K Sell
6,405
-218
-3% -$16.4K ﹤0.01% 1744
2022
Q1 		$549K Buy
+6,623
New +$488K ﹤0.01% 1718
2020
Q2 		– Sell
-36,576
Closed -$2.46M – 2335
2020
Q1 		$2.46M Sell
36,576
-1,147
-3% -$90.6K 0.03% 525
2019
Q4 		$3.18M Hold
37,723
– – 0.03% 600
2019
Q3 		$2.82M Buy
37,723
+4,562
+14% +$365K 0.03% 635
2019
Q2 		$2.1M Hold
33,161
– – 0.02% 794
2019
Q1 		$1.6M Buy
+33,161
New +$1.6M 0.02% 902

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

MetLife Investment Management's NVCR Position: Q1 2026 in Review

MetLife Investment Management reduced its NovoCure (NVCR) stake by 0.81% in Q1 2026, selling an estimated $5.75K and leaving 56,470 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

MetLife Investment Management first reported a position in NVCR in Q1 2019 and has held it in 21 quarters since. The position peaked at $3.18M in Q4 2019. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • MetLife Investment Management held 56,470 shares of NovoCure worth $616K as of Q1 2026.
  • MetLife Investment Management sold 460 NovoCure shares in Q1 2026, an estimated $5.75K.
  • NovoCure made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1653 holding.
  • MetLife Investment Management first reported a position in NovoCure in Q1 2019 and has held it in 21 quarters since.
  • MetLife Investment Management's NovoCure position peaked at $3.18M in Q4 2019.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.